MD 0727Alternative Names: MD-0727
Latest Information Update: 03 May 2011
At a glance
- Originator Microbia
- Developer Ironwood Pharmaceuticals
- Mechanism of Action Cholesterol absorption inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 21 Sep 2005 Phase-I clinical trials in Hypercholesterolaemia in USA (PO)